The therapeutics of Alzheimer's disease: where we stand and where we are heading (Q38392585)

2 September 2017

1 reference

title

The therapeutics of Alzheimer's disease: where we stand and where we are heading (English)

1 reference

2 September 2017

0 references

Dennis J Selkoe

1 reference

2 September 2017

language of work or name

1 reference

1 September 2013

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

328-336

1 reference

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

2 September 2017

cites work

1 reference

21 January 2018

1 reference

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

21 January 2018

1 reference

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

21 January 2018

1 reference

The natural history of cognitive decline in Alzheimer's disease

21 January 2018

1 reference

The neuropathology of probable Alzheimer disease and mild cognitive impairment

21 January 2018

1 reference

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

21 January 2018

1 reference

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

21 January 2018

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

Preventing Alzheimer's disease

21 January 2018

1 reference

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

21 January 2018

1 reference

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study

21 January 2018

1 reference

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

21 January 2018

1 reference

Alzheimer's disease and the amyloid β-protein

21 January 2018

1 reference

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

21 January 2018

1 reference

Identification of beta-secretase (BACE1) substrates using quantitative proteomics

21 January 2018

1 reference

Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons

21 January 2018

1 reference

Control of peripheral nerve myelination by the beta-secretase BACE1

21 January 2018

1 reference

Bace1 modulates myelination in the central and peripheral nervous system.

21 January 2018

1 reference

Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles

21 January 2018

1 reference

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation

21 January 2018

1 reference

Substrate-targeting gamma-secretase modulators

21 January 2018

1 reference

Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice

21 January 2018

1 reference

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

21 January 2018

1 reference

Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers

21 January 2018

1 reference

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

21 January 2018

1 reference

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

21 January 2018

1 reference

Immunology and immunotherapy of Alzheimer's disease

21 January 2018

1 reference

Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.

21 January 2018

1 reference

Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites

21 January 2018

1 reference

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

21 January 2018

1 reference

TREM2 Variants in Alzheimer's Disease

21 January 2018

1 reference

The classical complement cascade mediates CNS synapse elimination

21 January 2018

1 reference

Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease

21 January 2018

1 reference

Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).

21 January 2018

1 reference

A call for transparent reporting to optimize the predictive value of preclinical research

21 January 2018

1 reference

Believe it or not: how much can we rely on published data on potential drug targets?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.24001

1 reference

2 September 2017

1 reference